Aim of the study: To assess if elevated serum cystatin C (Cyst-C) is an indicator for renal or hepatic dysfunction in presence of liver fibrosis. Material and methods: Data of 50 children with chronic liver diseases (CLDs), out of which 25 were without renal impairment, and 25 with renal impairment were analyzed. Twenty healthy children served as a healthy control group. Routine investigations, creatinine clearance, hepatitis viral markers, abdominal ultrasonography, and liver biopsy were performed for patients with CLDs. Measurement of serum Cyst-C concentration by particle induced immunonephelometry were completed for both patients and control group. Results: Results showed that serum Cyst-C is not correlated with the degree of hepatic impairment (p > 0.05). Cyst-C levels were significantly higher in patients with renal impairment (3.66 ± 0.85) than those without (0.71 ± 0.12), and healthy control group (0.63 ± 0.85). Cystatin-C showed significant elevation in patients with severe fibrosis with renal impairment (3.66 ± 0.85) than those without (0.76 ± 0.04) (p < 0.0001). Cyst-C at cutoff levels of 1.65 mg/l showed 100% accuracy in discrimination between those with and those without renal impairment. Cyst-C > 2.34 mg/l predicting GFR < 40 ml/min with accuracy of 90%. Cyst-C > 2.73 mg/l predicting GFR < 20 ml/min with accuracy of 81.5%. Conclusions: Serum Cyst-C is a promising marker to estimate renal impairment in children with CLDs. Further studies are needed to estimate the accuracy of serum Cyst-C for early detection of renal impairment and close monitoring of the hepatic children.
Introduction
Chronic liver diseases (CLDs) are an important health issue since severe hepatic dysfunction could lead to persistent inflammation, necrosis, liver cirrho sis, and even hepatocellular carcinoma [1] . Hepato renal syndrome (HRS) is a reversible functional renal impairment that occurs in patients with advanced liv er cirrhosis or those with fulminant hepatic failure. It is characterized by marked reduction in glomerular filtration rate (GFR) and renal plasma flow (RPF) in the rimetric method of Cr determination by bilirubin and other compounds, which accumulate in liver failure. On the other hand, Cr is an imperfect filtration marker, because it is secreted by the tubular cells into the tu bular lumen, especially if renal function is impaired. When the GFR is low, the serum Cr and Cr clearance overestimate the true GFR. Some drugs (such as cime tidine or trimethoprim) have the effect of reducing tu bular secretion of Cr. Similarly, urea is synthesized by the liver and may be reduced as a consequence of he patic insufficiency [3] .
Creatinine clearance needs 24hours urine collection, therefore it's unreliable especially in outpatients, as the collection may be incomplete. This results in an underes timation of renal function [4] . Inulin clearance cost and technical difficulties preclude its routine use [3] . β 2 micro globulin is affected by presence of infections or malignan cies. Chromium 51 labeled ethylenediaminetetraacetic acid ( 51 CrEDTA) is costly, invasive, time consuming, and stressful for children and parents [5] .
Cystatin C (CystC), a low molecular weight pro tein produced at a constant rate by all nucleated cells, freely filtered across the glomerular membrane and neither secreted or absorbed, and completely catabo lized in the proximal tubule, independent of muscle mass, sex and age [3] . Plasma cystC is a new marker of GFR [6] , which provides accurate data for calculating GFR independent of the drug doses [7] .
The value of serum CystC as a marker for liver fibrosis and renal dysfunction in children with CLDs will be evaluated in our study.
Material and methods
Data of fifty children with CLDs with different eti ologies (Table 1) Twentyfive of them were without renal impairment (group 1), and 25 children with renal impairment (group 2), which was evaluated on the base of blood urea, serum Cr, and Cr clearance. Twenty healthy chil dren of matched age and sex serves as a healthy con trol group (group 3). All children were provided with a written informed consent that was signed by the par ents of each child in order to participate in the study, and for collection and storage of serum. The study was approved by the Research Ethics Committee of the National Liver Institute, Menofia University, and con forms to the 1975 Declaration of Helsinki.
Diagnosis of CLDs were based on clinical, biochem ical, serological, and histopathological investigations. All groups included in this study were investigated on the base of full medical history and through clinical ex aminations. Complete blood count (CBC), liver func tion tests (LFTs), complete urinalysis, blood urea, se rum Cr, and Cr clearance, hepatitis markers, especially hepatitis B (HB) surface antigen, antiHB core antibody, and hepatitis C virus (HCV) antibody were performed for all patients. Measurement of serum CystC con centration by particle induced immunonephelometry were performed for all patients and the control group. Abdominal ultrasonographic examination was com pleted to define the status of the liver, spleen, kidney, and other abdominal findings. Ultrasoundguided liver biopsy specimens were performed for all the patients. Serum samples were obtained, and renal functions were assessed by serum Cr, calculated GFR (CGFR) and se rum CystC measurement. Serum Cr was measured by Jaffe reaction using Bayer Dax 48 and expressed in micromole per liter. CGFR was obtained by applying the Schwartz formula: 
Results
In total, 50 children with CLDs were enrolled in the study; 25 of them without renal impairment (group 1) and 25 with renal impairment (group 2). Twenty healthy children (group 3) represented healthy control group. Group 1, group 2, and group 3 mean age were 8.9 ± 2.8, 10.2 ± 3.1, and 9.6 ± 4.6 years, respectively (p = 0.183). Males represented 64%, 64%, and 60% in group 1, group 2, and group 3, respectively (p = 0.916). On comparing, the levels of cystatinC between different etiologies in each group were found of no significant difference (Table 1) .
No statistical significant difference between group 1 and 2, with regards to CBC parameters and LFTs were found. Urea, Cr levels, and CystC levels were signifi cantly higher in group 2 than in group 1 and 3. Cr clear ance was significantly impaired in group 2, while no significant difference was found between group 1 and 3 (Table 2) . CystC, at a cutoff level of 1.65 mg/l had sensitivity, specificity, and positive predictive value (PPV). Negative predictive value (NPV) and accuracy of 100% in discrimination between those with renal impairment and those without (Fig. 1) were found. CystC > 2.34 mg/l predicting GFR < 40 ml/min with accuracy of 90%. CystC > 2.73 mg/l predicting GFR < 20 ml/min with accuracy of 81.5%. Significant cor relation between CystC and AST, ALT, and GGT was found in group 1, while we did not found similar re sults in group 2 (Table 3) . CystC was not correlated with the true function of the liver (albumin and pro thrombin) in any of both groups (Table 3 ).
On assessing the mean level of cystatinC in dif ferent grades of fibrosis, we found significant elevation in cystatinC level in kidney impaired patients with severe fibrosis (3.66 ± 0.85) than patients with severe fibrosis but with preserved kidney function (0.76 ± 0.04), and those with moderate (0.63 ± 0.12) and mild fibrosis (0.73 ± 0.14) (p < 0.0001).
Discussions
Attempts have been made to use noninvasive tech niques for assessment of the degree of liver fibrosis and renal impairment in hepatic children.
The current study showed that serum CystC levels is affected by the degree of kidney impairment (group 2). Serum CystC levels were closely correlated with the levels of urea, Cr, and CrGFR. In agreement with that of Park et al., an increased serum CystC levels were found to be related to decreased renal function [9] . Moreover, several reports have suggested that CystC is more sensitive than Cr in detecting reduced renal function, and its levels are a good marker for predicting HRS and survival in patients with cirrhotic ascites and normal Cr levels [10] . Gerbes et al. reported that serum CystC proved to be a valuable tool for early diagnosis of moderately impaired renal function in adult patient with cirrhosis [11] .
The absence of correlation between serum CystC and true functions of the liver (albumin and pro thrombin) is associated with significant elevation of CystC level in patients with severe fibrosis with renal impairment than in those without renal impairment. The nearer the levels of CystC in control group and in patients without renal impairment, and absence of association between CystC and the etiology of liver disease, reflects that the variations of CystC levels oc curred most likely according to the severity of renal impairment, rather than severity of the hepatic con dition. This was in accordance with a study done by Buyukberber et al., which may add to the accuracy of CystC in detecting kidney function [12] . In agreement with that, Orlando et al. reported that plasma CystC is a more accurate GFR marker in cirrhotic adult patients than plasma Cr and CrGFR [3] .
We had calculated a CystC cutoff point, validity in detecting cases of CLDs with renal impairment at 1.65 mg/l with 100% sensitivity and 100% specificity. CystC > 2.34 mg/l predicting GFR < 40 ml/min with accuracy of 90%. CystC > 2.73 mg/l predicting GFR < 20 ml/min with accuracy of 81.5%. Similar results were reported by Samyn et al.; they calculated a CystC cutoff point at 1.06 mg/l with 91% sensitivity and 81% specificity [5] . Also, Kim et al. presented that the cut off value of 1.1 mg/l could be an adequate reference levels for detecting early renal dysfunction in these patients [13] . Omar et al. found that serum CysC and CysCbased formulae were not only the best measures that reflected the actual renal performance in cirrhotic patients, but also the most accurate in detecting early stages of renal impairment in these patients [14] .
Conclusions
Serum CystC is a promising marker to estimate re nal impairment in children with CLDs. Further studies are needed to estimate the accuracy of serum CystC for early detection of renal impairment and close mon itoring of the hepatic children. 
